Author

J. Durivault

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

V. Vial· 3 shared C. Montemagno· 2 shared G. Pages· 2 shared R. Grepin· 2 shared V. Picco· 2 shared A. Broisat· 1 shared A. Vandenberghe· 1 shared B. Serrano· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

V. Vial

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Exploiting De Novo Serine Synthesis as a Metabolic Vulnerability to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

M. Teisseire, U. Sahu, J. Parola, M.-C. Tsai, V. Vial, J. Durivault, R. Grepin, Y. Cormerais, G. Pages, I. Ben-Sahra, S. Giuliano

This study identifies serine synthesis as a metabolic vulnerability in sunitinib-resistant renal cell carcinoma, showing that inhibiting key enzymes enhances drug sensitivity.

bioRxiv · Mar 22, 2024 · PreprintCancer Biology

Integrin-alpha V beta 3 is a fundamental factor in medulloblastoma tumorigenicity and radioresistance: A new game for an old player

W. Echavidre, J. Durivault, C. Gotorbe, T. Blanchard, M. Pagnuzzi, V. Vial, F. Raes, A. Broisat, R. Villeneuve, R. Amblard, N. Garnier, C. Ortholan, M. Faraggi, B. Serrano, V. Picco, C. Montemagno

This study investigates the role of integrin-v{beta}3 in medulloblastoma tumorigenicity and radioresistance, showing its correlation with radioresistance and response to cilengitide.

bioRxiv · Mar 8, 2023 · PreprintCancer Biology

The antiangiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma

M. Pagnuzzi-Boncompagni, V. Picco, V. Vial, V. Planas-Bielsa, A. Vandenberghe, R. Grepin, J. Durivault, C. Montemagno, S. Martial, J. Doyen, J. Gavard, G. Pages

This study evaluates axitinib's efficacy and safety in medulloblastoma, finding it has low toxicity and anti-tumoral effects in preclinical models and poor prognosis association in public databases.

bioRxiv · Sep 18, 2020 · PreprintCancer Biology